PMID- 19104504
OWN - NLM
STAT- MEDLINE
DCOM- 20090511
LR  - 20180822
IS  - 0818-9641 (Print)
IS  - 0818-9641 (Linking)
VI  - 87
IP  - 3
DP  - 2009 Mar-Apr
TI  - Type II-activated macrophages suppress the development of experimental autoimmune 
      encephalomyelitis.
PG  - 235-40
LID - 10.1038/icb.2008.99 [doi]
AB  - Treatment with immune complexes, which ligate Fcgamma receptors (FcgammaRs), 
      suppresses the development of experimental autoimmune encephalomyelitis (EAE). To 
      determine the mechanism of action, we investigated how these immune complexes 
      affected type II activation of macrophages (that is, exposure to immune complexes 
      in a proinflammatory environment). Our results show that lower doses of 
      interferon-gamma (IFN-gamma) were more effective at priming bone marrow-derived 
      macrophages (BMMphi) to produce more interleukin 10 (IL-10) and less IL-12p40 in 
      response to lipopolysaccharide (LPS) and immune complexes compared with LPS 
      alone. Moreover, at the lowest level of IFN-gamma (20 U ml(-1)), a significant 
      downregulation in the surface expression of CD40, CD80 and PD-L1 was observed in 
      LPS and immune complex-stimulated macrophages (that is, type II activated) than 
      macrophages stimulated with LPS alone (that is, classically activated). Finally, 
      treatment of mice with type II-activated macrophages protected them from 
      developing EAE, suggesting that administration of immune complexes is protective 
      against EAE by inducing type II-activated macrophages.
FAU - Tierney, Joanna B
AU  - Tierney JB
AD  - School of Biological Sciences, Victoria University of Wellington, Wellington, New 
      Zealand.
FAU - Kharkrang, Marie
AU  - Kharkrang M
FAU - La Flamme, Anne Camille
AU  - La Flamme AC
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20081223
PL  - United States
TA  - Immunol Cell Biol
JT  - Immunology and cell biology
JID - 8706300
RN  - 0 (Antigen-Antibody Complex)
RN  - 0 (B7-1 Antigen)
RN  - 0 (B7-H1 Antigen)
RN  - 0 (CD40 Antigens)
RN  - 0 (Cd274 protein, mouse)
RN  - 0 (Glycoproteins)
RN  - 0 (Immunologic Factors)
RN  - 0 (Interleukin-12 Subunit p40)
RN  - 0 (Lipopolysaccharides)
RN  - 0 (Membrane Glycoproteins)
RN  - 0 (Myelin-Oligodendrocyte Glycoprotein)
RN  - 0 (Peptide Fragments)
RN  - 0 (Peptides)
RN  - 0 (Receptors, IgG)
RN  - 0 (myelin oligodendrocyte glycoprotein (35-50), Ala(37)-)
RN  - 130068-27-8 (Interleukin-10)
RN  - 82115-62-6 (Interferon-gamma)
SB  - IM
MH  - Animals
MH  - Antigen-Antibody Complex/*administration & dosage
MH  - B7-1 Antigen/drug effects/immunology/metabolism
MH  - B7-H1 Antigen
MH  - CD40 Antigens/antagonists & inhibitors/immunology/metabolism
MH  - Down-Regulation/drug effects/immunology
MH  - Encephalomyelitis, Autoimmune, Experimental/immunology/*prevention & control
MH  - Glycoproteins/pharmacology
MH  - Immunologic Factors/*administration & dosage
MH  - Interferon-gamma/pharmacology
MH  - Interleukin-10/biosynthesis/immunology
MH  - Interleukin-12 Subunit p40/biosynthesis/immunology
MH  - Lipopolysaccharides/immunology
MH  - *Macrophage Activation
MH  - Macrophages/*drug effects/immunology
MH  - Membrane Glycoproteins/antagonists & inhibitors/immunology/metabolism
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Myelin-Oligodendrocyte Glycoprotein
MH  - Peptide Fragments/pharmacology
MH  - Peptides/antagonists & inhibitors/immunology/metabolism
MH  - Receptors, IgG/*immunology
EDAT- 2008/12/24 09:00
MHDA- 2009/05/12 09:00
CRDT- 2008/12/24 09:00
PHST- 2008/12/24 09:00 [entrez]
PHST- 2008/12/24 09:00 [pubmed]
PHST- 2009/05/12 09:00 [medline]
AID - icb200899 [pii]
AID - 10.1038/icb.2008.99 [doi]
PST - ppublish
SO  - Immunol Cell Biol. 2009 Mar-Apr;87(3):235-40. doi: 10.1038/icb.2008.99. Epub 2008 
      Dec 23.